Portal Hypertension

Categories: Cardiovascular diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Portal Hypertension

MalaCards integrated aliases for Portal Hypertension:

Name: Portal Hypertension 11 19 75 28 5 14 16 31 33
Hypertension, Portal 19 43 71
Pht - [portal Hypertension] 33
Hypertension Portal 53
Portal Htn 33


External Ids:

Disease Ontology 11 DOID:10762
ICD9CM 34 572.3
MeSH 43 D006975
NCIt 49 C3119
SNOMED-CT 68 155821005
ICD10 31 K76.6
UMLS 71 C0020541

Summaries for Portal Hypertension

GARD: 19 Portal hypertension is abnormally high blood pressure in branches of the portal vein, the large vein that brings blood from the intestine to the liver. Portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. It may be caused by a variety of conditions, but cirrhosis is the most common cause in Western countries.

MalaCards based summary: Portal Hypertension, also known as hypertension, portal, is related to portal hypertension, noncirrhotic, 2 and varicose veins, and has symptoms including signs and symptoms, digestive An important gene associated with Portal Hypertension is GIMAP5 (GTPase, IMAP Family Member 5), and among its related pathways/superpathways are Signal Transduction and Development Angiotensin activation of ERK. The drugs Carvedilol and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and bone marrow, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 Portal hypertension is abnormally increased portal venous pressure - blood pressure in the portal vein... more...

Related Diseases for Portal Hypertension

Diseases related to Portal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1054)
# Related Disease Score Top Affiliating Genes
1 portal hypertension, noncirrhotic, 2 33.0 GIMAP5 GIMAP1-GIMAP5
2 varicose veins 32.6 TNF F2 ELN
3 budd-chiari syndrome 32.4 JAK2 GPT F2 ALB
4 esophageal varix 32.4 THPO SST PKHD1 GPT F2 ALB
5 hypersplenism 32.4 THPO PKHD1 GPT F2 ALB
6 schistosomiasis 32.3 TNF GPT F2 ALB
7 cholangitis, primary sclerosing 32.3 TNF GPT F2 ALB
8 portal vein thrombosis 32.0 THPO JAK2 GPT F2 ALB
9 hepatic encephalopathy 31.8 TNF SST GPT F2 ALB
10 liver cirrhosis 31.8 UTS2 TNF THPO SST REN GPT
11 alcoholic liver cirrhosis 31.7 TNF GPT F2 ALB
12 liver disease 31.6 TNF THPO PKHD1 GPT F2 ALB
13 biliary atresia 31.4 GPT F2 ALB
14 active peptic ulcer disease 31.3 SST GPT F2 ALB
15 hepatorenal syndrome 31.3 REN GPT F2 EDN1 ALB ACE
16 non-alcoholic steatohepatitis 31.3 TNF GPT ALB
17 cholangitis 31.2 TNF SST GPT F2 ALB
18 viral hepatitis 31.2 THPO GPT F2 ALB
19 primary biliary cholangitis 31.2 TNF GPT F2 ALB
20 obstructive jaundice 31.2 SST GPT F2 ALB
21 pancytopenia 31.1 THPO GPT GIMAP5 F2 ALB ACE
22 alcohol use disorder 31.1 TNF GPT F2 ALB ACE
23 hemorrhoid 31.1 TNF GPT F2 ALB
24 arteriovenous malformation 31.0 F2 BMPR2 ALB
25 thrombocytopenia 31.0 TNF THPO JAK2 GPT F2 EDN1
26 hypertension, essential 31.0 UTS2 TNF SST REN NOS3 JAK2
27 hepatopulmonary syndrome 31.0 TNF NOS3 EDNRA EDN1 BMPR2 ALB
28 hepatic coma 31.0 GPT F2 ALB
29 thrombophilia 31.0 NOS3 JAK2 F2 ACE
30 autoimmune hepatitis 31.0 TNF GPT F2 ALB
31 systemic scleroderma 31.0 TNF EDNRA EDN1 ACE
32 hepatitis b 31.0 TNF GPT F2 ALB
33 wilson disease 31.0 GPT F2 ALB
34 alcoholic hepatitis 31.0 TNF GPT F2 ALB
35 sclerosing cholangitis 31.0 TNF GPT F2 ALB
36 splenic infarction 30.9 JAK2 GPT F2 ALB
37 vascular disease 30.9 TNF NOS3 F2 ELN EDN1 BMPR2
38 thrombocytosis 30.9 THPO JAK2 F2 ALB
39 cholelithiasis 30.9 SST GPT ALB
40 peliosis hepatis 30.8 GPT F2 ALB
41 cystic fibrosis 30.8 TNF NOS3 ELN EDNRA ALB ACE
42 telangiectasis 30.8 TNF ELN BMPR2
43 peptic ulcer disease 30.8 TNF SST GPT F2 ALB ACE
44 bile duct cysts 30.8 PKHD1 GPT ALB
45 bilirubin metabolic disorder 30.8 TNF GPT F2 ALB
46 cholecystitis 30.8 GPT F2 ALB
47 polycystic kidney disease 30.7 TNF SST REN PKHD1 ALB ACE
48 protein-losing enteropathy 30.7 GPT F2 ALB
49 disseminated intravascular coagulation 30.7 TNF GPT F2
50 abdominal tuberculosis 30.7 TNF GPT F2 ALB

Comorbidity relations with Portal Hypertension via Phenotypic Disease Network (PDN): (show all 22)

Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Chronic Kidney Disease
Deficiency Anemia Esophageal Varix
Heart Disease Hepatic Encephalopathy
Hepatitis Hepatocellular Carcinoma
Hepatorenal Syndrome Hypersplenism
Iron Deficiency Anemia Neutropenia
Portal Vein Thrombosis Primary Biliary Cholangitis
Protein-Energy Malnutrition Urea Cycle Disorder

Graphical network of the top 20 diseases related to Portal Hypertension:

Diseases related to Portal Hypertension

Symptoms & Phenotypes for Portal Hypertension

UMLS symptoms related to Portal Hypertension:

signs and symptoms, digestive

MGI Mouse Phenotypes related to Portal Hypertension:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 ACE AGTR1 ALB BMPR2 DGUOK EDN1
2 growth/size/body region MP:0005378 10.33 ACE AGTR1 BMPR2 DGUOK EDN1 EDNRA
3 normal MP:0002873 10.25 ALB BMPR2 EDN1 EDNRA F2 JAK2
4 renal/urinary system MP:0005367 10.24 ACE AGTR1 ALB BMPR2 DGUOK EDN1
5 cardiovascular system MP:0005385 10.24 ACE AGTR1 ALB BMPR2 DGUOK EDN1
6 liver/biliary system MP:0005370 10.21 ACE ALB DGUOK GIMAP1-GIMAP5 GIMAP5 JAK2
7 immune system MP:0005387 10.2 ACE AGTR1 ALB BMPR2 EDNRA F2
8 muscle MP:0005369 10.18 ALB BMPR2 EDN1 EDNRA ELN F2
9 endocrine/exocrine gland MP:0005379 10.17 ACE ALB EDN1 EDNRA F2 GIMAP1-GIMAP5
10 digestive/alimentary MP:0005381 10.1 ALB EDN1 EDNRA F2 GIMAP1-GIMAP5 GIMAP5
11 adipose tissue MP:0005375 10.04 ACE AGTR1 DGUOK F2 NOS3 SST
12 skeleton MP:0005390 9.93 BMPR2 DGUOK EDN1 EDNRA ELN F2
13 respiratory system MP:0005388 9.91 BMPR2 EDNRA ELN F2 JAK2 NOS3
14 hematopoietic system MP:0005397 9.77 ACE AGTR1 BMPR2 EDNRA F2 GIMAP1-GIMAP5
15 mortality/aging MP:0010768 9.55 ACE AGTR1 ALB BMPR2 DGUOK EDN1

Drugs & Therapeutics for Portal Hypertension

Drugs for Portal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
Nitric Oxide Approved Phase 4 10102-43-9 145068
Simvastatin Approved Phase 4 79902-63-9 54454
Nadolol Approved Phase 4 42200-33-9 39147
Isosorbide dinitrate Approved, Investigational Phase 4 87-33-2 3780 6883
Isosorbide Approved, Investigational Phase 4 652-67-5 99937 12597
Prazosin Approved Phase 4 19216-56-9 4893
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
Dipyridamole Approved Phase 4 58-32-2 3108
Nadroparin Approved, Investigational Phase 4
Reviparin Approved, Investigational Phase 4 9041-08-1
Apixaban Approved Phase 4 503612-47-3 10182969
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
Lactulose Approved Phase 4 4618-18-2 11333
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
25 Anti-Arrhythmia Agents Phase 4
26 Neurotransmitter Agents Phase 4
27 Adrenergic beta-Antagonists Phase 4
28 Adrenergic Antagonists Phase 4
29 Adrenergic alpha-Antagonists Phase 4
30 Adrenergic alpha-1 Receptor Antagonists Phase 4
31 Hormones Phase 4
32 Adrenergic Agents Phase 4
33 Antihypertensive Agents Phase 4
34 calcium channel blockers Phase 4
35 Antioxidants Phase 4
36 Protective Agents Phase 4
37 Hypoglycemic Agents Phase 4
38 Antineoplastic Agents, Hormonal Phase 4
39 Vasoconstrictor Agents Phase 4
40 Antimetabolites Phase 4
41 Hypolipidemic Agents Phase 4
42 Anticholesteremic Agents Phase 4
43 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
44 Lipid Regulating Agents Phase 4
45 diuretics Phase 4
46 Sympatholytics Phase 4
47 Isosorbide-5-mononitrate Phase 4
48 Hormone Antagonists Phase 4
49 Proton Pump Inhibitors Phase 4
50 Diuretics, Potassium Sparing Phase 4

Interventional clinical trials:

(show top 50) (show all 237)
# Name Status NCT ID Phase Drugs
1 Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial. Unknown status NCT04353193 Phase 4 Terlipressin;Octreotide
2 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
3 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
4 A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir and Carvedilol in Moderate and Severe Cirrhotic Portal Hypertension Due to Hepatitis B Virus Unknown status NCT02945982 Phase 4 Entecavir+Carvedilol;Entecavir+Carvedilol+ Fuzheng Huayu
5 A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus Unknown status NCT02945956 Phase 4 Entecavir;Entecavir + Fuzheng Huayu
6 Early Precise Diagnosis and Intervention of Cirrhotic Portal Hypertension (CPT) Based on a Noninvasive 3D-virtual-model of Hepatic Portal System (3D-vHPS) Unknown status NCT02925975 Phase 4 Carvedilol
7 Somatostatin as Inflow Modulator in Adult-to-adult Living Donor Liver Transplantation: a Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT04107428 Phase 4 Somatostatin;Placebo
8 Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding. Unknown status NCT00414713 Phase 4
9 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
10 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
11 Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response Unknown status NCT00563602 Phase 4
12 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
13 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Completed NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
14 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
15 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
16 Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Completed NCT02994485 Phase 4 Simvastatin
17 Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices Completed NCT00534677 Phase 4 Terlipressin;Octreotide
18 Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
19 Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
20 The Effect of Oral Taurine on Portal Hemodynamics in Patients With Advanced Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
21 Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis Completed NCT00570622 Phase 4 Pioglitazone;Placebo
22 Effects of Spironolactone on Fibrosis Progression and Portal Pressure in Patients With Advanced Chronic Liver Disease Completed NCT02907749 Phase 4 Spironolactone and carvedilol;Carvedilol
23 A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Completed NCT03175731 Phase 4 Proton Pump Inhibitors;Placebo
24 Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. Recruiting NCT04073290 Phase 4 Rifaximin 550 milligram Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 milligram/milliliter Oral Solution
25 Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy Recruiting NCT04645550 Phase 4 Apixaban;Warfarin;Aspirin;Dipyridamole;Low molecular weight heparin
26 Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
27 Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension (DPH Trial) Unknown status NCT02975323 Phase 3 Carvedilol
28 Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis Unknown status NCT02643212 Phase 3 Rivaroxaban;Placebo
29 Effect of Administration "Add on" of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
30 Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study Unknown status NCT01560845 Phase 2, Phase 3
31 Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. Unknown status NCT01798329 Phase 3
32 Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
33 The Effect of Somatostatin in the Regulation of Velocity and Blood Flow of the Hepatic Circulation in Patients Undergoing Liver Resection Unknown status NCT04010669 Phase 3 Somatostatin;Placebo
34 Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices Completed NCT00493480 Phase 3 carvedilol;propranolol
35 Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
36 Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial Completed NCT01000779 Phase 3 Propranolol
37 Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis Completed NCT00006398 Phase 3 Timolol Maleate;Placebo
38 The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension Completed NCT00331188 Phase 3 Sanvar® (vapreotide)
39 Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Completed NCT01456286 Phase 2, Phase 3 sapropterin
40 Vonoprazan vs. Pantoprazole in the Prevention of Post Endoscopic Band Ligation Ulcer/Bleeding in Portal Hypertensive Patients: A Randomized Controlled Trial Completed NCT05227833 Phase 3 Vonoprazan fumarate (Vonaspire);Pantoprazole 40mg
41 Control of Acute Variceal Bleeding Using the Multi-shooter Band Ligator Compared to Injection Sclerotherapy. Completed NCT01131962 Phase 3
42 The Effectiveness of L-ornithine-L-aspartate on Plasma Ammonia in Cirrhotic Patients After TIPS Procedure: a Prospective, Randomized, Controlled, Open-label Clinical Trial Completed NCT01440829 Phase 2, Phase 3 L-ornithine-L-aspartate
43 A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding Completed NCT01095185 Phase 3 Simvastatin;Placebo
44 Propranolol, Carvedilol and Rosuvastatin in the Prevention of Recurrent Variceal Haemorrhage in Patients With Cirrhotic Portal Hypertension Recruiting NCT03720067 Phase 2, Phase 3 Propranolol;Carvedilol;Rosuvastatin;Placebo
45 Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension Recruiting NCT04007289 Phase 3 Apixaban;Placebo
46 Hepatic Resection Versus Radiofrequency Ablation for Patients With Hepatocellular Carcinoma and Portal Hypertension Recruiting NCT02192671 Phase 3
47 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Not yet recruiting NCT05470205 Phase 3 SHAPE measurement (Sonazoid ultrasoud contrast agent);SHAPE measurement (Definity ultrasoud contrast agent)
48 A Phase 3 Study of Carvedilol vs Variceal Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding Withdrawn NCT02066649 Phase 3 Carvedilol
49 Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using Thalidomide Withdrawn NCT00787436 Phase 3 Thalidomide
50 Impact and Safety of a Physical Training Program on Health-related Quality of Life in Patients With Cirrhosis and Portal Hypertension Completed NCT00517738 Phase 2

Search NIH Clinical Center for Portal Hypertension

Cochrane evidence based reviews: hypertension, portal

Genetic Tests for Portal Hypertension

Genetic tests related to Portal Hypertension:

# Genetic test Affiliating Genes
1 Portal Hypertension 28

Anatomical Context for Portal Hypertension

Organs/tissues related to Portal Hypertension:

MalaCards : Liver, Spleen, Bone Marrow, Endothelial, Kidney, Pancreas, Bone

Publications for Portal Hypertension

Articles related to Portal Hypertension:

(show top 50) (show all 19771)
# Title Authors PMID Year
GIMAP5 maintains liver endothelial cell homeostasis and prevents portal hypertension. 62 5
33956074 2021
Long-acting somatostatin analogue therapy in obscure-overt gastrointestinal bleeding in noncirrhotic portal hypertension: a case report and literature review. 53 62
19491695 2010
Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. 53 62
20428787 2010
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. 53 62
19582578 2010
Long-term outcome and management of hepatopulmonary syndrome in children. 53 62
19686444 2010
Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. 53 62
19797237 2009
Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients. 53 62
19796042 2009
Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. 53 62
19446911 2009
Reticulated platelets and thrombopoietin in schistosomiasis patients. 53 62
19143871 2009
Pathobiology of secondary immune thrombocytopenia. 53 62
19245930 2009
Ascites: aetiology, mortality and the prevalence of spontaneous bacterial peritonitis. 53 62
19440927 2009
Innate immune dysfunction in acute and chronic liver disease. 53 62
20047110 2009
Anicteric cholangiopathy in schistosomiasis patients. 53 62
18598665 2008
Cannabinoid receptors as therapeutic targets in the management of liver diseases. 53 62
19259549 2008
Increased circulating urotensin II in cirrhosis: potential implications in liver disease. 53 62
17913301 2008
Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. 53 62
18318439 2008
[The role of urotensin II in human pathophysiology]. 53 62
19323069 2008
[Analysis of risk factors for selective devascularization in patients with portal hypertension]. 53 62
18509995 2008
New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. 53 62
17608670 2007
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. 53 62
17918268 2007
Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. 53 62
18023093 2007
Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. 53 62
17958515 2007
Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. 53 62
17919235 2007
Other immune thrombocytopenias. 53 62
18096469 2007
Right liver lobe/albumin ratio: contribution to non-invasive assessment of portal hypertension. 53 62
17879402 2007
The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece? 53 62
17879360 2007
Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. 53 62
17417733 2007
Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. 53 62
17608860 2007
The role of thrombopoietin and spleen volume in thrombocytopenia of patients with noncirrhotic and cirrhotic portal hypertension. 53 62
17602356 2007
Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. 53 62
17337499 2007
Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. 53 62
17174610 2007
Q-T interval (QT(C)) in patients with cirrhosis: relation to vasoactive peptides and heart rate. 53 62
17852825 2007
A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. 53 62
17416468 2007
New insights into the coagulopathy of liver disease and liver transplantation. 53 62
17203512 2006
[Prevention and treatment of esophageal variceal bleeding]. 53 62
17378164 2006
Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. 53 62
16919014 2006
Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. 53 62
16434427 2006
Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. 53 62
16771945 2006
Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. 53 62
16573786 2006
GRK2 makes trouble: a no-NO in portal hypertension. 53 62
16530538 2006
Myosin phosphatase isoform switching in vascular smooth muscle development. 53 62
16356512 2006
[Hepatorenal syndrome]. 53 62
17203812 2006
Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis. 53 62
15955217 2005
Expression of angiotensin II type 1 receptor in human cirrhotic livers: Its relation to fibrosis and portal hypertension. 53 62
15905119 2005
The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. 53 62
15929762 2005
[A study of the association of iNOS and eNOS gene polymorphism with portal hypertension in liver cirrhosis]. 53 62
15918973 2005
Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension. 53 62
15647641 2005
Urotensin II: its function in health and its role in disease. 53 62
15883758 2005
Hepatorenal syndrome. 53 62
15381144 2005
Hepatorenal syndrome. 53 62
15920325 2005

Variations for Portal Hypertension

ClinVar genetic disease variations for Portal Hypertension:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 GIMAP1-GIMAP5, GIMAP5 NM_018384.5(GIMAP5):c.140T>C (p.Ile47Thr) SNV Likely Pathogenic
1344844 GRCh37: 7:150439367-150439367
GRCh38: 7:150742279-150742279
2 GIMAP1-GIMAP5, GIMAP5 NM_018384.5(GIMAP5):c.667C>T (p.Leu223Phe) SNV Likely Pathogenic
1344845 GRCh37: 7:150439894-150439894
GRCh38: 7:150742806-150742806
3 GIMAP1-GIMAP5, GIMAP5 NM_018384.5(GIMAP5):c.326C>T (p.Pro109Leu) SNV Likely Pathogenic
1344846 GRCh37: 7:150439553-150439553
GRCh38: 7:150742465-150742465
4 GIMAP1-GIMAP5, GIMAP5 NM_018384.5(GIMAP5):c.611T>C (p.Leu204Pro) SNV Likely Pathogenic
1188820 GRCh37: 7:150439838-150439838
GRCh38: 7:150742750-150742750

Expression for Portal Hypertension

Search GEO for disease gene expression data for Portal Hypertension.

Pathways for Portal Hypertension

Pathways related to Portal Hypertension according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
12.56 NOS3 JAK2 F2 EDN1 AGTR1
Show member pathways
Show member pathways
Show member pathways
Show member pathways
7 11.41 TNF ELN EDN1
Show member pathways
9 10.94 JAK2 EDNRA EDN1
10 10.82 NOS3 EDNRA EDN1

GO Terms for Portal Hypertension

Cellular components related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.98 UTS2 TNF THPO SST REN PKHD1
2 extracellular space GO:0005615 9.64 ACE ALB BMPR2 EDN1 F2 GPT

Biological processes related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 10.21 REN PKHD1 AGTR1 ACE
2 positive regulation of inflammatory response GO:0050729 10.17 TNF JAK2 AGTR1 ACE
3 positive regulation of cytosolic calcium ion concentration GO:0007204 10.13 AGTR1 EDN1 EDNRA JAK2 UTS2
4 response to hypoxia GO:0001666 10.11 UTS2 TNF EDNRA EDN1 ACE
5 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 10.1 TNF JAK2 EDN1
6 response to xenobiotic stimulus GO:0009410 10.1 UTS2 TNF SST REN EDN1 ACE
7 positive regulation of nitric oxide biosynthetic process GO:0045429 10.08 TNF JAK2 EDN1
8 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.07 F2 JAK2 TNF
9 respiratory gaseous exchange by respiratory system GO:0007585 10.03 EDN1 EDNRA ELN
10 regulation of vasoconstriction GO:0019229 9.97 ACE AGTR1 EDN1
11 vasoconstriction GO:0042310 9.95 EDNRA EDN1 ACE
12 noradrenergic neuron differentiation GO:0003357 9.94 EDNRA EDN1
13 cardiac neural crest cell migration involved in outflow tract morphogenesis GO:0003253 9.94 EDNRA EDN1
14 cellular response to luteinizing hormone stimulus GO:0071373 9.93 EDNRA EDN1
15 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.93 NOS3 EDN1
16 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.92 ACE AGTR1
17 negative regulation of renal sodium excretion GO:0035814 9.9 UTS2 ACE
18 regulation of blood pressure GO:0008217 9.9 ACE EDN1 EDNRA NOS3 REN UTS2
19 sympathetic neuron axon guidance GO:0097492 9.88 EDNRA EDN1
20 neural crest cell fate commitment GO:0014034 9.88 EDNRA EDN1
21 blood vessel remodeling GO:0001974 9.86 NOS3 EDNRA BMPR2 ACE
22 endothelin receptor signaling pathway involved in heart process GO:0086101 9.85 EDNRA EDN1
23 pharyngeal arch artery morphogenesis GO:0061626 9.85 BMPR2 EDN1 EDNRA
24 renin-angiotensin regulation of aldosterone production GO:0002018 9.84 REN AGTR1
25 meiotic cell cycle process involved in oocyte maturation GO:1903537 9.83 EDNRA EDN1
26 cellular response to human chorionic gonadotropin stimulus GO:0044751 9.81 EDNRA EDN1
27 response to lipopolysaccharide GO:0032496 9.73 TNF THPO REN NOS3 JAK2 EDN1
28 regulation of biological quality GO:0065008 9.5 EDN1 EDNRA TNF
29 blood vessel diameter maintenance GO:0097746 9.28 UTS2 NOS3 EDN1 AGTR1 ACE

Molecular functions related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.76 UTS2 THPO SST EDN1
2 signaling receptor binding GO:0005102 9.4 UTS2 TNF THPO REN JAK2 F2
3 bradykinin receptor binding GO:0031711 9.26 AGTR1 ACE

Sources for Portal Hypertension

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....